drugset / Trial / NCT02693613

Pharmacokinetic Study of ASP1517 With Kremezin®

NCT02693613

Phase 1 Completed 34 enrolled Astellas Pharma Inc Kyntra Bio · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study is to evaluate the effect of Kremezin® on the pharmacokinetics of single dose of ASP1517 in healthy non-elderly adult male subjects when administered concomitantly or in a time separated manner.

Timeline

Start
2016-02
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Activated Charcoal Other / unclassified
Subject Roxadustat Small molecule

Indications

No indication recorded.